nach oben

Inflammation

Erschienen in:

10.03.2023 | REVIEW

Therapeutic Potential of Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis

verfasst von: Jie Gao, Hongliang Zhang, Yanyan Yang, Jinhui Tao

Erschienen in: Inflammation | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome is a cytoplasmic multiprotein complex composed of the innate immune receptor protein NLRP3, the adapter protein apoptosis-associate speck-like protein containing a caspase recruitment domain (ASC), and the inflammatory protease cysteine-1. Pathogen-associated molecular patterns (PAMPs) or other endogenous danger-associated molecular patterns (DAMPs) activate the NLRP3 inflammasome. As part of the innate immune response, activated NLRP3 promotes GSDMD-dependent pyroptosis, and IL-1β and IL-18 are released during inflammation. Aberrantly activated NLRP3 is deeply involved in various inflammatory diseases. Due to its interaction with adaptive immunity. NLRP3 inflammation has increasingly received attention in autoimmune diseases. Rheumatoid arthritis (RA) is a classic autoimmune disease, which mainly causes bone and cartilage damage. Elevated levels of NLRP3 can be detected in the synovium of RA patients. NLRP3 overactivation is strongly associated with RA activity. Mouse models of spontaneous arthritis has shown that NLRP3/IL-1β axis is implicated in periarticular inflammation in RA. In this review, we describe the current understanding of NLRP3 activation in RA pathogenesis and dissect its impact on innate and adaptive immunity. We also discuss the potential application of specific inhibitors of NLRP3 to provide new therapeutic strategies for treating RA.

Aletaha, D., T. Neogi, A.J. Silman, J. Funovits, D.T. Felson, C.O. Bingham 3rd., et al. 2010. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism 62: 2569–2581. https://doi.org/10.1002/art.27584.CrossRefPubMed

McInnes, I.B., and G. Schett. 2011. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine 365: 2205–2219. https://doi.org/10.1056/NEJMra1004965.CrossRefPubMed

Smolen, J.S., D. Aletaha, and I.B. McInnes. 2016. Rheumatoid arthritis. Lancet 388: 2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8.CrossRefPubMed

Chatzidionysiou, K., S. Emamikia, J. Nam, S. Ramiro, J. Smolen, D. van der Heijde, et al. 2017. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: A systematic literature review informing the 2016 update of The EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases 76: 1102–1107. https://doi.org/10.1136/annrheumdis-2016-210711.CrossRefPubMed

Ramiro, S., A. Sepriano, K. Chatzidionysiou, J.L. Nam, J.S. Smolen, D. van der Heijde, et al. 2017. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases 76: 1101–1136. https://doi.org/10.1136/annrheumdis-2016-210708.CrossRefPubMed

van Walsem, A., S. Pandhi, R.M. Nixon, P. Guyot, A. Karabis, and R.A. Moore. 2015. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: A network meta-analysis. Arthritis Research & Therapy 17: 66. https://doi.org/10.1186/s13075-015-0554-0.CrossRef

Ravindran, V., S. Rachapalli, and E.H. Choy. 2009. Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: A meta-analysis. Rheumatology (Oxford) 48: 807–811. https://doi.org/10.1093/rheumatology/kep096.CrossRefPubMed

Strangfeld, A., F. Hierse, R. Rau, G.R. Burmester, B. Krummel-Lorenz, W. Demary, et al. 2010. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Research & Therapy 12. https://doi.org/10.1186/ar2904.

Mercer, L.K., J. Askling, P. Raaschou, W.G. Dixon, L. Dreyer, M.L. Hetland, et al. 2017. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: Results from a collaborative project of 11 European biologic registers. Annals of the Rheumatic Diseases 76: 386–391. https://doi.org/10.1136/annrheumdis-2016-209285.CrossRefPubMed

10.

Liston, A., and S.L. Masters. 2017. Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nature Reviews Immunology 17: 208–214. https://doi.org/10.1038/nri.2016.151.CrossRefPubMed

11.

Ben Hamad, M., F. Cornelis, S. Marzouk, G. Chabchoub, Z. Bahloul, A. Rebai, et al. 2012. Association study of CARD8 (p.C10X) and NLRP3 (p.Q705K) variants with rheumatoid arthritis in French and Tunisian populations. International Journal of Immunogenetics, 39:131–136. https://doi.org/10.1111/j.1744-313X.2011.01070.x.

12.

Shao, S., C.J. Chen, G.N. Shi, Y. Zhou, Y.Z. Wei, N.Y. Fan, et al. 2021. Therapeutic potential of the target on NLRP3 inflammasome in multiple sclerosis. Pharmacology and Therapeutics 227. https://doi.org/10.1016/j.pharmthera.2021.107880.

13.

Dalbeth, N., A.L. Gosling, A. Gaffo, and A. Abhishek. 2021. Gout. Lancet 397:1843–1855. https://doi.org/10.1016/S0140-6736(21)00569-9.

14.

Li, Z., J. Guo, and L. Bi. 2020. Role of the NLRP3 inflammasome in autoimmune diseases. Biomedicine and Pharmacotherapy 130: 110542. https://doi.org/10.1016/j.biopha.2020.110542.

15.

Xia, S., L.R.t. Hollingsworth, and H. Wu. 2020. Mechanism and regulation of gasdermin-mediated cell death. Cold Spring Harbor Perspectives in Biology 12. https://doi.org/10.1101/cshperspect.a036400.

16.

Dekkers, J., R.E. Toes, T.W. Huizinga, and D. van der Woude. 2016. The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis. Current Opinion in Rheumatology 28: 275–281. https://doi.org/10.1097/BOR.0000000000000277.CrossRefPubMed

17.

Lacerte, P., A. Brunet, B. Egarnes, B. Duchene, J.P. Brown, and J. Gosselin. 2016. Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists. Arthritis Research & Therapy 18: 10. https://doi.org/10.1186/s13075-015-0901-1.CrossRef

18.

Yu, M., H.C. Wang, A.H. Ding, D.T. Golenbock, E. Latz, C.J. Czura, et al. 2006. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26: 174–179. https://doi.org/10.1097/01.shk.0000225404.51320.82.CrossRefPubMed

19.

Jiang, C.S., W.H. Zhu, J. Xu, B. Wang, W.K. Hou, R. Zhang, et al. 2014. MicroRNA-26a negatively regulates toll-like receptor 3 expression of rat macrophages and ameliorates pristane induced arthritis in rats. Arthritis Research & Therapy 16. https://doi.org/10.1186/ar4435.

20.

Elshabrawy, H.A., A.E. Essani, Z. Szekanecz, D.A. Fox, and S. Shahrara. 2017. TLRs, future potential therapeutic targets for RA. Autoimmunity Reviews 16: 103–113. https://doi.org/10.1016/j.autrev.2016.12.003.CrossRefPubMed

21.

Clanchy, F.I.L., F. Borghese, J. Bystrom, A. Balog, H. Penn, D.N. Hull, et al. 2021. TLR expression profiles are a function of disease status in rheumatoid arthritis and experimental arthritis. Journal of Autoimmunity 118. https://doi.org/10.1016/j.jaut.2021.102597.

22.

Sakalyte, R., J. Denkovskij, E. Bernotiene, S. Stropuviene, S.O. Mikulenaite, G. Kvederas, et al. 2021. The expression of inflammasomes NLRP1 and NLRP3, Toll-like receptors, and vitamin D receptor in synovial fibroblasts from patients with different types of knee arthritis. Frontiers in Immunology 12: 767512. https://doi.org/10.3389/fimmu.2021.767512.

23.

Brand, D.D., K.A. Latham, and E.F. Rosloniec. 2007. Collagen-induced arthritis. Nature Protocols 2: 1269–1275. https://doi.org/10.1038/nprot.2007.173.CrossRefPubMed

24.

Chen, S.Y., A.L. Shiau, Y.T. Li, Y.S. Lin, C.H. Lee, C.L. Wu, et al. 2012. Suppression of collagen-induced arthritis by intra-articular lentiviral vector-mediated delivery of toll-like receptor 7 short hairpin RNA gene. Gene Therapy 19: 752–760. https://doi.org/10.1038/gt.2011.173.CrossRefPubMed

25.

Sacre, S.M., E. Andreakos, S. Kiriakidis, P. Amjadi, A. Lundberg, G. Giddins, et al. 2007. The toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. American Journal of Pathology 170: 518–525. https://doi.org/10.2353/ajpath.2007.060657.CrossRefPubMedPubMedCentral

26.

Huang, Q.Q., R. Sobkoviak, A.R. Jockheck-Clark, B. Shi, A.M. Mandelin, P.P. Tak, et al. 2009. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. Journal of Immunology 182: 4965–4973. https://doi.org/10.4049/jimmunol.0801563.CrossRef

27.

Unterberger, S., K.A. Davies, S.B. Rambhatla, and S. Sacre. 2021. Contribution of toll-like receptors and the NLRP3 inflammasome in rheumatoid arthritis pathophysiology. Immunotargets Ther 10: 285–298. https://doi.org/10.2147/Itt.S288547.CrossRefPubMedPubMedCentral

28.

Sokolove, J., X.Y. Zhao, P.E. Chandra, and W.H. Robinson. 2011. Immune complexes containing citrullinated fibrinogen costimulate macrophages via toll-like receptor 4 and Fc gamma receptor. Arthritis Rheum-Us 63: 53–62. https://doi.org/10.1002/art.30081.CrossRef

29.

Dong, X., Z. Zheng, P. Lin, X. Fu, F. Li, J. Jiang, et al. 2020. ACPAs promote IL-1beta production in rheumatoid arthritis by activating the NLRP3 inflammasome. Cellular & Molecular Immunology 17: 261–271. https://doi.org/10.1038/s41423-019-0201-9.CrossRef

30.

Yang, Q.D., W.H. Zhao, Y.Y. Chen, Y. Chen, J.L. Shi, R. Qin, et al. 2021. RelA/microRNA-30a/NLRP3 signal axis is involved in rheumatoid arthritis via regulating NLRP3 inflammasome in macrophages. Cell Death and Disease 12. https://doi.org/10.1038/s41419-021-04349-5.

31.

Laurent, L., C. Clavel, O. Lemaire, F. Anquetil, M. Cornillet, L. Zabraniecki, et al. 2011. Fc gamma receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Annals of the Rheumatic Diseases 70: 1052–1059. https://doi.org/10.1136/ard.2010.142091.CrossRefPubMed

32.

Liu, Y., W. Wei, Y. Wang, C. Wan, Y. Bai, X. Sun, et al. 2019. TNF-alpha/calreticulin dual signaling induced NLRP3 inflammasome activation associated with HuR nucleocytoplasmic shuttling in rheumatoid arthritis. Inflammation Research 68: 597–611. https://doi.org/10.1007/s00011-019-01244-w.CrossRefPubMed

33.

Zucal, C., V. D'Agostino, R. Loffredo, B. Mantelli, NatthakanThongon, P. Lal, et al. 2015. Targeting the multifaceted HuR protein, benefits and caveats. Current Drug Targets 16: 499–515. https://doi.org/10.2174/1389450116666150223163632.

34.

Swanson, K.V., M. Deng, and J.P. Ting. 2019. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nature Reviews Immunology 19: 477–489. https://doi.org/10.1038/s41577-019-0165-0.CrossRefPubMedPubMedCentral

35.

Dayer, J.M. 2003. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 42 Suppl 2: ii3–10. https://doi.org/10.1093/rheumatology/keg326.

36.

Munoz-Planillo, R., P. Kuffa, G. Martinez-Colon, B.L. Smith, T.M. Rajendiran, and G. Nunez. 2013. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38: 1142–1153. https://doi.org/10.1016/j.immuni.2013.05.016.CrossRefPubMedPubMedCentral

37.

Fan, Z.D., Y.Y. Zhang, Y.H. Guo, N. Huang, H.H. Ma, H. Huang, et al. 2016. Involvement of P2X7 receptor signaling on regulating the differentiation of Th17 cells and type II collagen-induced arthritis in mice. Scientific Reports United Kingdom 6. https://doi.org/10.1038/srep35804.

38.

Portales-Cervantes, L., P. Nino-Moreno, L. Doniz-Padilla, L. Baranda-Candido, M. Garcia-Hernandez, M. Salgado-Bustamante, et al. 2010. Expression and function of the P2X(7) purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Human Immunology 71: 818–825. https://doi.org/10.1016/j.humimm.2010.05.008.CrossRefPubMed

39.

Purohit, R., A.K. Bera. 2021. Pannexin 1 plays a pro-survival role by attenuating P2X7 receptor-mediated Ca2+ influx. Cell Calcium 99. https://doi.org/10.1016/j.ceca.2021.102458.

40.

Li, Y.Y., Y. Shen, K. Jin, Z.K. Wen, W.Q. Cao, B.W. Wu, et al. 2019. The DNA repair nuclease MRE11A functions as a mitochondrial protector and prevents T cell pyroptosis and tissue inflammation. Cell Metabolism, 2019;30: 477-+. https://doi.org/10.1016/j.cmet.2019.06.016.

41.

Hofer, A.M., and E.M. Brown. 2003. Extracellular calcium sensing and signalling. Nature Reviews Molecular Cell Biology 4: 530–538. https://doi.org/10.1038/nrm1154.CrossRefPubMed

42.

Liao, J., S. Zhang, S. Yang, Y. Lu, K. Lu, Y. Wu et al. Interleukin-6-mediated-Ca(2+) handling abnormalities contributes to atrial fibrillation in sterile pericarditis rats. Frontiers in Immunology, 2021;12: 758157. https://doi.org/10.3389/fimmu.2021.758157.

43.

Paccou, J., C. Boudot, C. Renard, S. Liabeuf, S. Kamel, P. Fardellone, et al. 2014. Total calcium-sensing receptor expression in circulating monocytes is increased in rheumatoid arthritis patients with severe coronary artery calcification. Annals of the Rheumatic Diseases 73: 846–846. https://doi.org/10.1136/annrheumdis-2014-eular.2377.CrossRef

44.

Lee, G.S., N. Subramanian, A.I. Kim, I. Aksentijevich, R. Goldbach-Mansky, D.B. Sacks, et al. 2012. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492: 123-+. https://doi.org/10.1038/nature11588.

45.

Rossol, M., M. Pierer, N. Raulien, D. Quandt, U. Meusch, K. Rothe, et al. 2012. Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nature Communications 3. https://doi.org/10.1038/ncomms2339.

46.

Damgaard, D., L. Senolt, M.F. Nielsen, G.J. Pruijn, and C.H. Nielsen. 2014. Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen. Arthritis Research & Therapy 16. https://doi.org/10.1186/s13075-014-0498-9.

47.

Bonavita, E., S. Gentile, M. Rubino, V. Maina, R. Papait, P. Kunderfranco, et al. 2015. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 160: 700–714. https://doi.org/10.1016/j.cell.2015.01.004.CrossRefPubMed

48.

Shimada, K., T.R. Crother, J. Karlin, J. Dagvadorj, N. Chiba, S. Chen, et al. 2012. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36: 401–414. https://doi.org/10.1016/j.immuni.2012.01.009.CrossRefPubMedPubMedCentral

49.

Contis, A., S. Mitrovic, J. Lavie, I. Douchet, E. Lazaro, M.E. Truchetet, et al. 2017. Neutrophil-derived mitochondrial DNA promotes receptor activator of nuclear factor kappaB and its ligand signalling in rheumatoid arthritis. Rheumatology (Oxford) 56: 1200–1205. https://doi.org/10.1093/rheumatology/kex041.CrossRefPubMed

50.

Zhou, R., A.S. Yazdi, P. Menu, and J. Tschopp. 2011. A role for mitochondria in NLRP3 inflammasome activation. Nature 469: 221–225. https://doi.org/10.1038/nature09663.CrossRefPubMed

51.

Nakahira, K., J.A. Haspel, V.A. Rathinam, S.J. Lee, T. Dolinay, H.C. Lam, et al. 2011. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nature Immunology 12: 222–230. https://doi.org/10.1038/ni.1980.CrossRefPubMed

52.

Weyand, C.M., and J.J. Goronzy. 2020. Immunometabolism in the development of rheumatoid arthritis. Immunological Reviews 294: 177–187. https://doi.org/10.1111/imr.12838.CrossRefPubMedPubMedCentral

53.

Zhong, Z., Y. Zhai, S. Liang, Y. Mori, R. Han, F.S. Sutterwala, et al. 2013. TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nature Communications 4: 1611. https://doi.org/10.1038/ncomms2608.CrossRefPubMed

54.

Mills, E., and L.A. O’Neill. 2014. Succinate: A metabolic signal in inflammation. Trends in Cell Biology 24: 313–320. https://doi.org/10.1016/j.tcb.2013.11.008.CrossRefPubMed

55.

Borenstein, D.G., C.A. and Gibbs, R.P. Jacobs. 1982. Gas-liquid chromatographic analysis of synovial fluid. Succinic acid and lactic acid as markers for septic arthritis. Arthritis & Rheumatology 25: 947–53. https://doi.org/10.1002/art.1780250806.

56.

Littlewood-Evans, A., S. Sarret, V. Apfel, P. Loesle, J. Dawson, J. Zhang, et al. 2016. GPR91 senses extracellular succinate released from inflammatory macrophages and exacerbates rheumatoid arthritis. Journal of Experimental Medicine 213: 1655–1662. https://doi.org/10.1084/jem.20160061.CrossRefPubMedPubMedCentral

57.

Dinarello, C.A. 2013. The C3a receptor, caspase-1, and release of IL-1beta. Blood 122: 3394–3395. https://doi.org/10.1182/blood-2013-08-518282.CrossRefPubMedPubMedCentral

58.

Friscic, J., M. Bottcher, C. Reinwald, H. Bruns, B. Wirth, S.J. Popp, et al. 2021. The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts. Immunity, 54: 1002-+. https://doi.org/10.1016/j.immuni.2021.03.003.

59.

Wu, X.Y. 2020. Complement C1q synergizes with PTX3 in promoting NLRP3 inflammasome over-activation and pyroptosis in rheumatoid arthritis. Journal of Immunology 204.

60.

Lu, J.H., Y.Q. Liu, Q.W. Deng, Y.P. Peng, and Y.H. Qiu. 2015. Dopamine D2 receptor is involved in alleviation of type II collagen-induced arthritis in mice. Biomed Research International 2015. https://doi.org/10.1155/2015/496759.

61.

Hornung, V., F. Bauernfeind, A. Halle, E.O. Samstad, H. Kono, K.L. Rock, et al. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunology 9: 847–856. https://doi.org/10.1038/ni.1631.CrossRefPubMedPubMedCentral

62.

Mathews, R.J., J.I. Robinson, M. Battellino, C. Wong, J.C. Taylor, G. Biologics in Rheumatoid Arthritis, et al. 2014. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Annals of the Rheumatic Disease 73: 1202–10. https://doi.org/10.1136/annrheumdis-2013-203276.

63.

Shin, T.H., H.S. Kim, T.W. Kang, B.C. Lee, H.Y. Lee, Y.J. Kim, et al. 2016. Human umbilical cord blood-stem cells direct macrophage polarization and block inflammasome activation to alleviate rheumatoid arthritis. Cell Death Disease 7. https://doi.org/10.1038/cddis.2016.442.

64.

Kolly, L., M. Karababa, L.A.B. Joosten, S. Narayan, R. Salvi, V. Petrilli, et al. 2009. Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF. Journal of Immunology 183: 4003–4012. https://doi.org/10.4049/jimmunol.0802173.CrossRef

65.

Ippagunta, S.K., D.D. Brand, J.W. Luo, K.L. Boyd, C. Calabrese, R. Stienstra, et al. 2010. Inflammasome-independent role of apoptosis-associated speck-like protein containing a CARD (ASC) in T cell priming is critical for collagen-induced arthritis. Journal of Biological Chemistry 285: 12454–12462. https://doi.org/10.1074/jbc.M109.093252.CrossRefPubMedPubMedCentral

66.

Zhang, Y.F., Y. Zheng, H.B. Li. 2016. NLRP3 inflammasome plays an important role in the pathogenesis of collagen-induced arthritis. Mediators Inflammation 2016. https://doi.org/10.1155/2016/9656270.

67.

Taniguchi, S., and J. Sagara. 2007. Regulatory molecules involved in inflammasome formation with special reference to a key mediator protein. ASC. Semin Immunopathol 29: 231–238. https://doi.org/10.1007/s00281-007-0082-3.CrossRefPubMed

68.

Martinon, F., A. Mayor, and J. Tschopp. 2009. The inflammasomes: Guardians of the body. Annual Review of Immunology 27: 229–265. https://doi.org/10.1146/annurev.immunol.021908.132715.CrossRefPubMed

69.

Vande Walle, L., N. Van Opdenbosch, P. Jacques, A. Fossoul, E. Verheugen, P. Vogel, et al. 2014. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512: 69-+. https://doi.org/10.1038/nature13322.

70.

Yin, Z., S. Siegert, L. Neure, M. Grolms, L. Liu, U. Eggens, et al. 1999. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology 38: 1058–1067. https://doi.org/10.1093/rheumatology/38.11.1058.CrossRefPubMed

71.

Dolhain, R.J.E.M., A.N. vanderHeiden, N.T. terHaar, F.C. Breedveld, A.M.M. Miltenburg. 1996. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheumatoid-Us 39: 1961–1969. https://doi.org/10.1002/art.1780391204.

72.

Park, S.H., D.J. Min, M.L. Cho, W.U. Kim, J. Youn, W. Park, et al. 2001. Shift toward T helper 1 cytokines by type II collagen-reactive T cells in patients with rheumatoid arthritis. Arthritis Rheum-Us 44: 561–569. https://doi.org/10.1002/1529-0131(200103)44:3%3c561::Aid-Anr104%3e3.0.Co;2-Z.CrossRef

73.

Schulze-Koops, H., and J.K. Kalden. 2001. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 15: 677–691. https://doi.org/10.1053/berh.2001.0187.CrossRef

74.

Wu, S.Y., Y.O. Zhou, S.J. Liu, H.L. Zhang, H. Luo, X.X. Zuo, et al. 2018. Regulatory effect of nicotine on the differentiation of Th1, Th2 and Th17 lymphocyte subsets in patients with rheumatoid arthritis. European Journal of Pharmacology 831: 38–45. https://doi.org/10.1016/j.ejphar.2018.04.028.CrossRefPubMed

75.

Bao, Y., J. Peng, K.L. Yang, C.H. Wang, Y.F. Guo, Z.S. Guo, et al. 2022. Therapeutic effects of Chinese medicine Di-Long (Pheretima vulgaris) on rheumatoid arthritis through inhibiting NF-kappaB activation and regulating Th1/Th2 balance. Biomed Pharmacotherapy 147: 112643. https://doi.org/10.1016/j.biopha.2022.112643.

76.

Almeida, A.R.M., N. Legrand, M. Papiernik, and A.A. Freitas. 2002. Homeostasis of peripheral CD4(+) T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4(+) T cell numbers. Journal of Immunology 169: 4850–4860. https://doi.org/10.4049/jimmunol.169.9.4850.CrossRef

77.

Kelchtermans, H., B. De Klerck, T. Mitera, M. Van Balen, D. Bullens, A. Billiau, et al. 2005. Defective CD4(+)CD25(+) regulatory T cell functioning in collagen-induced arthritis: An important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Research & Therapy 7: R402–R415. https://doi.org/10.1186/ar1500.CrossRef

78.

Kawashima, M., and P. Miossec. 2005. mRNA quantification of T-bet, GATA-3, IFN-gamma, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: Link with disease activity. Journal of Clinical Immunology 25: 209–214. https://doi.org/10.1007/s10875-005-4092-4.CrossRefPubMed

79.

vanRoon, J.A.G., C.M. Verhoef, J.L.A.M. vanRoy, F.H.J. GmeligMeyling, O. HuberBruning, F.P. J.G. Lafeber, et al. 1997. Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Annals of the Rheumatic Disease 56: 656–660.https://doi.org/10.1136/ard.56.11.656.

80.

Lohr, J., B. Knoechel, J.J. Wang, A.V. Villarino, and A.K. Abbas. 2006. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. Journal of Experimental Medicine 203: 2785–2791. https://doi.org/10.1084/jem.20061341.CrossRefPubMedPubMedCentral

81.

Voll, R.E., and J.R. Kalden. 2005. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Annals. New York Academy of Sciences 1051: 799–810. https://doi.org/10.1196/annals.1361.123.CrossRef

82.

Kosmaczewska, A., J. Swierkot, L. Ciszak, and P. Wiland. 2011. The role of Th1, Th17, and Treg cells in the pathogenesis of rheumatoid arthritis including anti-inflammatory action of Th1 cytokines. Postępy Higieny i Medycyny Doświadczalnej 65: 397–403. https://doi.org/10.5604/17322693.948971.CrossRefPubMed

83.

Arbore, G., E.E. West, R. Spolski, A.A.B. Robertson, A. Klos, C. Rheinheimer, et al. 2016. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells. Science 352. https://doi.org/10.1126/science.aad1210.

84.

Zhao, C., Y. Gu, X. Zeng, and J. Wang. 2018. NLRP3 inflammasome regulates Th17 differentiation in rheumatoid arthritis. Clinical Immunology 197: 154–160. https://doi.org/10.1016/j.clim.2018.09.007.CrossRefPubMed

85.

Furst, D.E., and P. Emery. 2014. Rheumatoid arthritis pathophysiology: Update on emerging cytokine and cytokine-associated cell targets. Rheumatology 53: 1560–1569. https://doi.org/10.1093/rheumatology/ket414.CrossRefPubMedPubMedCentral

86.

Schenk, U., M. Frascoli, M. Proietti, R. Geffers, E. Traggiai, J. Buer, et al. 2011. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Science Signaling 4. https://doi.org/10.1126/scisignal.2001270.

87.

Konttinen, Y.T., J. Mandelin, T.F. Li, J. Salo, J. Lassus, M. Liljestrom, et al. 2002. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheumatoid-US 46: 953–960. https://doi.org/10.1002/art.10185.CrossRef

88.

Cascao, R., B. Vidal, H. Raquel, A. Neves-Costa, N. Figueiredo, V. Gupta, et al. 2012. Effective treatment of rat adjuvant-induced arthritis by celastrol. Autoimmunity Reviews 11: 856–862. https://doi.org/10.1016/j.autrev.2012.02.022.CrossRefPubMedPubMedCentral

89.

Omenetti, S., and T.T. Pizarro. 2015. The Treg/Th17 axis: A dynamic balance regulated by the gut microbiome. Frontiers in Immunology 6: 639. https://doi.org/10.3389/fimmu.2015.00639.CrossRefPubMedPubMedCentral

90.

Berner, B., D. Akca, T. Jung, G.A. Muller, and M.A. Reuss-Borst. 2000. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. Journal of Rheumatology 27: 1128–1135.PubMed

91.

Cosmi, L., F. Liotta, E. Lazzeri, M. Francalanci, R. Angeli, B. Mazzinghi, et al. 2003. Human CD8(+)CD25(+) thymocytes share phenotypic and functional features with CD4(+)CD25(+) re latory thyrnocytes. Blood 102: 4107–4114. https://doi.org/10.1182/blood-2003-04-1320.CrossRefPubMed

92.

Carvalheiro, H., J.A.P. da Silva, and M.M. Souto-Carneiro. 2013. Potential roles for CD8(+) T cells in rheumatoid arthritis. Autoimmunity Reviews 12: 401–409. https://doi.org/10.1016/j.autrev.2012.07.011.CrossRefPubMed

93.

Tripathy, A., S. Khanna, P. Padhan, S. Smita, S. Raghav, B. Gupta. 2017. Direct recognition of LPS drive TLR4 expressing CD8(+) T cell activation in patients with rheumatoid arthritis. Scientific Reports-UK 7. https://doi.org/10.1038/s41598-017-01033-7.

94.

Tripathy, A., P. Padhan, N. Swain, S.K. Raghav, and B. Gupta. 2021. Increased extracellular ATP in plasma of rheumatoid arthritis patients activates CD8(+) T cells. Archives of Medical Research 52: 423–433. https://doi.org/10.1016/j.arcmed.2020.12.010.CrossRefPubMed

95.

Russell, J.H., and T.J. Ley. 2002. Lymphocyte-mediated cytotoxicity. Annual Review of Immunology 20: 323–370. https://doi.org/10.1146/annurev.immunol.20.100201.131730.CrossRefPubMed

96.

Floudas, A., N. Neto, V. Marzaioli, K. Murray, B. Moran, M. Monaghan, et al. 2020. Pathogenic, glycolytic PD-1(+) B cells accumulate in the hypoxic RA joint. Arthritis Rheumatology 72. https://doi.org/10.1172/jci.insight.139032.

97.

Duddy, M.E., A. Alter, and A. Bar-Or. 2004. Distinct profiles of human B cell effector cytokines: A role in immune regulation? Journal of Immunology 172: 3422–3427. https://doi.org/10.4049/jimmunol.172.6.3422.CrossRef

98.

Moura, R.A., R. Cascao, I. Perpetuo, H. Canhao, E. Vieira-Sousa, A.F. Mourao, et al. 2011. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology 50: 278–282. https://doi.org/10.1093/rheumatology/keq338.CrossRefPubMed

99.

Zhang, L.L., H. Xiao, F. Zhang, Y.J. Wu, J.L. Shu, Y. Li, et al. 2021. BAFF, involved in B cell activation through the NF-kappa B pathway, is related to disease activity and bone destruction in rheumatoid arthritis. Acta Pharmacologica Sinica 42: 1665–1675. https://doi.org/10.1038/s41401-020-00582-4.CrossRefPubMedPubMedCentral

100.

Lim, K.H., L.C. Chen, K.T. Hsu, C.C. Chang, C.Y. Chang, C.W. Kao, et al. 2020. BAFF-driven NLRP3 inflammasome activation in B cells. Cell Death Disease 11. https://doi.org/10.1038/s41419-020-03035-2.

101.

Lamkanfi, M., J.L. Mueller, A.C. Vitari, S. Misaghi, A. Fedorova, K. Deshayes, et al. 2009. Glyburide inhibits the cryopyrin/Nalp3 inflammasome. Journal of Cell Biology 187: 61–70. https://doi.org/10.1083/jcb.200903124.CrossRefPubMedPubMedCentral

102.

Lipinski, M.J., and J.C. Frias. 2014. Molecule 16673–34-0: A new tool in our arsenal against inflammation. J Cardiovasc Pharm 63: 314–315. https://doi.org/10.1097/Fjc.0000000000000070.CrossRef

103.

Guo, C.Q., J.W. Fulp, Y.Q. Jiang, X. Li, J.E. Chojnacki, J.D. Wu, et al. 2017. Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis. ACS Chemical Neuroscience 8: 2194–2201. https://doi.org/10.1021/acschemneuro.7b00124.CrossRefPubMed

104.

Wu, F.P., J.F. Gao, J. Kang, X.X. Wang, Q. Niu, J.X. Liu, et al. 2021. B cells in rheumatoid arthritis:pathogenic mechanisms and treatment prospects. Frontiers in Immunology 12. https://doi.org/10.3389/fimmu.2021.750753.

105.

Collins, L.V., S. Hajizadeh, E. Holme, I.M. Jonsson, and A. Tarkowski. 2004. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. Journal of Leukocyte Biology 75: 995–1000. https://doi.org/10.1189/jlb.0703328.CrossRefPubMed

106.

Boyle, W.J., W.S. Simonet, and D.L. Lacey. 2003. Osteoclast differentiation and activation. Nature 423: 337–342. https://doi.org/10.1038/nature01658.CrossRefPubMed

107.

Gelderman, K.A., M. Hultqvist, A. Pizzolla, M. Zhao, K.S. Nandakumar, R. Mattsson, et al. 2007. Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species. The Journal of Clinical Investigation 117: 3020–3028. https://doi.org/10.1172/Jci31935.CrossRefPubMedPubMedCentral

108.

Zeisbrich, M., R.E. Yanes, H. Zhang, R. Watanabe, Y.Y. Li, L. Brosig, et al. 2018. Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation. Annals of the Rheumatic Diseases 77: 1053–1062. https://doi.org/10.1136/annrheumdis-2017-212647.CrossRefPubMed

109.

Gordon, M.K., and R.A. Hahn. 2010. Collagens. Cell and Tissue Research 339: 247–257. https://doi.org/10.1007/s00441-009-0844-4.CrossRefPubMed

110.

Zhong, Z., E. Sanchez-Lopez, and M. Karin. 2016. Autophagy, NLRP3 inflammasome and auto-inflammatory/immune diseases. Clinical and Experimental Rheumatology 34: 12–16.PubMed

111.

Yang, W., Z. Zhu, L. Li, A. McVicar, N. Gao, L. Wang, et al. 2020. Silencing of Ac45 simultaneously inhibits osteoclast-mediated bone resorption and attenuates dendritic cell-mediated inflammation through impairing acidification and cathepsin K secretion. Infect Immunology 89. https://doi.org/10.1128/IAI.00436-20.

112.

Guo, C., R. Fu, S. Wang, Y. Huang, X. Li, M. Zhou, et al. 2018. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clinical and Experimental Immunology 194: 231–243. https://doi.org/10.1111/cei.13167.CrossRefPubMedPubMedCentral

113.

Ishida, M., N. Kawao, Y. Mizukami, Y. Takafuji, H. Kaji. 2021. Serpinb1a suppresses osteoclast formation. Biochemistry and Biophysics Reports 26: 101004. https://doi.org/10.1016/j.bbrep.2021.101004.

114.

Richard, E.T., K. Morinaga, Y. Zheng, O. Sundberg, A. Hokugo, K. Hui, et al. 2021. Design and synthesis of cathepsin-K-activated osteoadsorptive fluorogenic sentinel (OFS) probes for detecting early osteoclastic bone resorption in a multiple myeloma mouse model. Bioconjugate Chemistry 32: 916–927. https://doi.org/10.1021/acs.bioconjchem.1c00036.CrossRefPubMedPubMedCentral

115.

Bartok, B., and G.S. Firestein. 2010. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunological Reviews 233: 233–255. https://doi.org/10.1111/j.0105-2896.2009.00859.x.CrossRefPubMedPubMedCentral

116.

Neybecker, P., C. Henrionnet, E. Pape, L. Grossin, D. Mainard, L. Galois, et al. 2020. Respective stemness and chondrogenic potential of mesenchymal stem cells isolated from human bone marrow, synovial membrane, and synovial fluid. Stem Cell Research & Therapy 11: 316. https://doi.org/10.1186/s13287-020-01786-5.CrossRef

117.

Trabandt, A., R.E. Gay, H.G. Fassbender, and S. Gay. 1991. Cathepsin-B in synovial-cells at the site of joint destruction in rheumatoid-arthritis. Arthritis Rheum-Us 34: 1444–1451.CrossRef

118.

Cunnane, G., O. FitzGerald, K.M. Hummel, R.E. Gay, S. Gay, and B. Bresnihan. 1999. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology 38: 34–42. https://doi.org/10.1093/rheumatology/38.1.34.CrossRefPubMed

119.

Mangan, M.S.J., E.J. Olhava, W.R. Roush, H.M. Seidel, G.D. Glick, and E. Latz. 2018. Targeting the NLRP3 inflammasome in inflammatory diseases. Nature Reviews. Drug Discovery 17: 588–606. https://doi.org/10.1038/nrd.2018.97.CrossRefPubMed

120.

Tenshin, H., J. Teramachi, M. Ashtar, M. Hiasa, Y. Inoue, A. Oda, et al. 2022. TGF-beta-activated kinase-1 inhibitor LL-Z1640–2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF-alpha and RANKL expression. Clinical and Translational Immunology 11: e1371. https://doi.org/10.1002/cti2.1371.

121.

Itoh, Y. 2017. Metalloproteinases in rheumatoid arthritis: Potential therapeutic targets to improve current therapies. Prog Mol Biol Transl 148: 327–338. https://doi.org/10.1016/bs.pmbts.2017.03.002.CrossRef

122.

Coll, R.C., J.R. Hill, C.J. Day, A. Zamoshnikova, D. Boucher, N.L. Massey, et al. 2019. MCC950 directly targets the NLRP3 ATP- hydrolysis motif for inflammasome inhibition. Nature Chemical Biology 15: 556-+. https://doi.org/10.1038/s41589-019-0277-7.

123.

Coll, R.C., A.A.B. Robertson, J.J. Chae, S.C. Higgins, R. Munoz-Planillo, M.C. Inserra, et al. 2015. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine 21: 248-+. https://doi.org/10.1038/nm.3806.

124.

Rao, Z.B., X. Chen, J.X. Wu, M.J. Xiao, J. Zhang, B.H. Wang, et al. 2019. Vitamin D receptor inhibits NLRP3 activation by impeding its BRCC3-mediated deubiquitination. Frontiers in Immunology 10. https://doi.org/10.3389/fimmu.2019.02783.

125.

Jiang, H., H.B. He, Y. Chen, W. Huang, J.B. Cheng, J. Ye, et al. 2017. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. Journal of Experimental Medicine 214: 3219–3238. https://doi.org/10.1084/jem.20171419.CrossRefPubMedPubMedCentral

126.

Zhang, Y., Z. Lin, D. Chen, and Y. He. 2021. CY-09 attenuates the progression of osteoarthritis via inhibiting NLRP3 inflammasome-mediated pyroptosis. Biochemical and Biophysical Research Communications 553: 119–125. https://doi.org/10.1016/j.bbrc.2021.03.055.CrossRefPubMed

127.

Smits, P. 1997. Cardiovascular effects of sulphonylurea derivatives. Diabetologia 40: S160–S161. https://doi.org/10.1007/s001250051438.CrossRefPubMed

128.

Marchetti, C., B. Swartzwelter, M.I. Koenders, T. Azam, I.W. Tengesdal, N. Powers, et al. 2018. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Research & Therapy 20. https://doi.org/10.1186/s13075-018-1664-2.

129.

Oizumi, T., T. Mayanagi, Y. Toya, T. Sugai, T. Matsumoto, and K. Sobue. 2022. NLRP3 inflammasome inhibitor OLT1177 suppresses onset of inflammation in mice with dextran sulfate sodium-induced colitis. Digest Diseases and Sciences 67: 2912–2921. https://doi.org/10.1007/s10620-021-07184-y.CrossRef

130.

He, Y., S. Varadarajan, R. Munoz-Planillo, A. Burberry, Y. Nakamura, and G. Nunez. 2014. 3,4-Methylenedioxy-beta-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. Journal of Biological Chemistry 289: 1142–1150. https://doi.org/10.1074/jbc.M113.515080.CrossRefPubMed

131.

Zheng, J.J., Z.X. Jiang, Y. Song, S. Huang, Y.Z. Du, X.B. Yang, et al. 2022. 3,4-Methylenedioxy-beta-nitrostyrene alleviates dextran sulfate sodium-induced mouse colitis by inhibiting the NLRP3 inflammasome. Frontiers in Pharmacology 13. https://doi.org/10.3389/fphar.2022.866228.

132.

Hu, J.J., X. Liu, S.Y. Xia, Z.B. Zhang, Y. Zhang, J.X. Zhao, et al. 2020. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nature Immunology 21: 736-+.https://doi.org/10.1038/s41590-020-0669-6.

133.

Sollberger, G., A. Choidas, G.L. Burn, P. Habenberger, R. Di Lucrezia, S. Kordes, et al. 2018. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Science Immunology 3. https://doi.org/10.1126/sciimmunol.aar6689.

134.

Mertens, M., and J.A. Singh. 2009. Anakinra for rheumatoid arthritis. Cochrane Database Systematic Review. https://doi.org/10.1002/14651858.CD005121.pub3:CD005121;10.1002/14651858.CD005121.pub3.CrossRef

135.

Curtis, J.R., and J.A. Singh. 2011. Use of biologics in rheumatoid arthritis: Current and emerging paradigms of care. Clinical Therapeutics 33: 679–707. https://doi.org/10.1016/j.clinthera.2011.05.044.CrossRefPubMedPubMedCentral

136.

Bullock, J., S.A.A. Rizvi, A.M. Saleh, S.S. Ahmed, D.P. Do, R.A. Ansari, et al. 2018. Rheumatoid arthritis: A brief overview of the treatment. Medical Principles and Practice 27: 501–507. https://doi.org/10.1159/000493390.CrossRefPubMedPubMedCentral

137.

Alten, R., H. Gram, L.A. Joosten, W.B. van den Berg, J. Sieper, S. Wassenberg, et al. 2008. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Research & Therapy 10. https://doi.org/10.1186/ar2438.

138.

Alten, R., J. Gomez-Reino, P. Durez, A. Beaulieu, A. Sebba, G. Krammer, et al. 2011. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study. BMC Musculoskeletal Disorders 12: 153. https://doi.org/10.1186/1471-2474-12-153.CrossRefPubMedPubMedCentral

139.

Kotter, I., and G. Horneff. 2010. IL-1 antagonists. Zeitschrift fur Rheumatologie 69: 581–593. https://doi.org/10.1007/s00393-009-0530-7.CrossRefPubMed

140.

Stahl, N., A. Radin, and S. Mellis. 2009. Rilonacept–CAPS and beyond. Annals of the New York Academy of Sciences 1182: 124–134. https://doi.org/10.1111/j.1749-6632.2009.05074.x.CrossRefPubMed

141.

He, H.B., H. Jiang, Y. Chen, J. Ye, A. L. Wang, C. Wang, et al. 2018. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nature Communications 9. https://doi.org/10.1038/s41467-018-04947-6.

142.

Jiang, W., M.Q. Li, F. He, S.B. Zhou, L.L. Zhu. 2017. Targeting the NLRP3 inflammasome to attenuate spinal cord injury in mice. Journal of Neuroinflammation 14. https://doi.org/10.1186/s12974-017-0980-9.

143.

Sanchez-Fernandez, A., D.B. Skouras, C.A. Dinarello, R. Lopez-Vales. 2019. OLT1177 (Dapansutrile), a selective NLRP3 inflammasome inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis. Frontiers in Immunology. 10. https://doi.org/10.3389/fimmu.2019.02578.

144.

Aslam, M.M., P. John, A. Bhatti, S. Jahangir, M.I. Kamboh. 2019. Vitamin D as a principal factor in mediating rheumatoid arthritis-derived immune response. Biomed Research International 2019. https://doi.org/10.1155/2019/3494937.

145.

Jeffery, L.E., K. Raza, and M. Hewison. 2016. Vitamin D in rheumatoid arthritis - towards clinical application. Nature Reviews Rheumatology 12: 201–210. https://doi.org/10.1038/nrrheum.2015.140.CrossRefPubMed

146.

Marchetti, C., B. Swartzwelter, F. Gamboni, C.P. Neff, K. Richter, T. Azam, et al. 2018. OLT1177, a ss-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proceedings of the National Academy of Sciences USA 115: E1530–E1539. https://doi.org/10.1073/pnas.1716095115.CrossRef

147.

Kluck, V., T.L.T.A. Jansen, M. Janssen, A. Comarniceanu, M. Efde, I.W. Tengesdal, et al. 2020. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: An open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol 2: E270–E280. https://doi.org/10.1016/S2665-9913(20)30065-5.CrossRefPubMedPubMedCentral

148.

Lonnemann, N., S. Hosseini, C. Marchetti, D.B. Skouras, D. Stefanoni, A. D’Alessandro, et al. 2020. The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences USA 117: 32145–32154. https://doi.org/10.1073/pnas.2009680117.CrossRef

149.

Lunding, L.P., D.B. Skouras, C. Vock, C.A. Dinarello, and M. Wegmann. 2022. The NLRP3 inflammasome inhibitor, OLT1177 (R), ameliorates experimental allergic asthma in mice. Allergy 77: 1035-+. https://doi.org/10.1111/all.15164.

150.

Yang, Y., H.N. Wang, M. Kouadir, H.H. Song, and F.S. Shi. 2019. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death and Disease 10. https://doi.org/10.1038/s41419-019-1413-8.

151.

Wang, W.Y., Y.C. Wu, and C.C. Wu. 2006. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Molecular Pharmacology 70: 1380–1389. https://doi.org/10.1124/mol.106.023986.CrossRefPubMed

152.

Patel, D., S. Gaikwad, N. Challagundla, M. Nivsarkar, and R. Agrawal-Rajput. 2018. Spleen tyrosine kinase inhibition ameliorates airway inflammation through modulation of NLRP3 inflammosome and Th17/Treg axis. International Immunopharmacology 54: 375–384. https://doi.org/10.1016/j.intimp.2017.11.026.CrossRefPubMed

153.

Zhang, Y., and Y. Zheng. 2016. Effects and mechanisms of potent caspase-1 inhibitor VX765 treatment on collagen-induced arthritis in mice. Clinical and Experimental Rheumatology 34: 111–118.PubMed

154.

Zhang, L., R.L. Xing, Z.Q. Huang, N.S. Zhang, L. Zhang, X.C. Li, et al. 2019. Inhibition of synovial macrophage pyroptosis alleviates synovitis and fibrosis in knee osteoarthritis. Mediators of Inflammation 2019. https://doi.org/10.1155/2019/2165918.

155.

Wright, C., and R.D. Moore. 1990. Disulfiram treatment of alcoholism. American Journal of Medicine 88: 647–655. https://doi.org/10.1016/0002-9343(90)90534-K.CrossRefPubMed

156.

Liu, Z.Y., X.Q. Yao, W.S. Jiang, W. Li, S.Y. Zhu, C.R. Liao, et al. 2020. Advanced oxidation protein products induce microglia-mediated neuroinflammation via MAPKs-NF-kappa B signaling pathway and pyroptosis after secondary spinal cord injury. Journal of Neuroinflammation 17. https://doi.org/10.1186/s12974-020-01751-2.

157.

Yu, E., E. Zhang, X. Lv, L. Yan, Z. Lin, F. Siaw-Debrah, et al. 2022. LDC7559 exerts neuroprotective effects by inhibiting GSDMD-dependent pyroptosis of microglia in mice with traumatic brain injury. Journal of Neurotrauma. https://doi.org/10.1089/neu.2021.0318;10.1089/neu.2021.0318.CrossRefPubMed

158.

Surprenant, A., F. Rassendren, E. Kawashima, R.A. North, and G. Buell. 1996. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272: 735–738. https://doi.org/10.1126/science.272.5262.735.CrossRefPubMed

159.

Arleevskaya, M.I., R.V. Larionova, W.H. Brooks, E. Bettacchioli, and Y. Renaudineau. 2020. Toll-like receptors, infections, and rheumatoid arthritis. Clinical Reviews in Allergy & Immunology 58: 172–181. https://doi.org/10.1007/s12016-019-08742-z.CrossRef

Titel: Therapeutic Potential of Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis
verfasst von: Jie Gao
Hongliang Zhang
Yanyan Yang
Jinhui Tao
Publikationsdatum: 10.03.2023
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 3/2023
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-023-01795-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Therapeutic Potential of Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Chlorogenic Acid Alleviates Hepatic Ischemia–Reperfusion Injury by Inhibiting Oxidative Stress, Inflammation, and Mitochondria-Mediated Apoptosis In Vivo and In Vitro

Nitric Oxide, Neutrophil/Lymphocyte, and Platelet/Lymphocyte Ratios as Promising Inflammatory Biomarkers in Complicated Crohn’s Disease: Outcomes of Corticosteroids and Anti-TNF-α Therapies

Fibrosis in Liver and Pancreas: a Review on Pathogenic Significance, Diagnostic Options, and Current Management Strategies

Recombinant Irisin Protects Against Alveolar Bone Destruction During Orthodontic Tooth Movement

Deletion of Cyclic GMP-AMP Synthase Aggravates Concanavalin A-Induced Acute Hepatic Injury by Facilitating Leukocyte Chemotaxis

miR-7-5p Antagomir Protects Against Inflammation-Mediated Apoptosis and Lung Injury via Targeting Raf-1 In Vitro and In Vivo

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin